B+
Bull case
25%
Probability
Target price
$28.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
STRO
Sutro BiopharmaANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Early STRO-004 responses, favorable reported tolerability and rapid enrollment could support meaningful revaluation if dose optimization confirms a usable therapeutic window. Timely STRO-006, STRO-227 and partnered-program advancement would broaden validation beyond one asset [#SEC-8K-2026-08-12].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +22.6.
What can break
STRO-004 efficacy is based on preliminary Phase 1 observations across multiple tumor types, including unconfirmed responses, and may not persist with additional follow-up or larger cohorts.
Momentum
4
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $17.00 · Bull $28.00 · Bear $8.00Analysis 2026-09-12; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-12 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $47.23
Why
Momentum4 · Δ7d -0.6
Value41 · Δ7d -0.0
Sentiment100 · Δ7d +22.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +22.6.
Contradictions & invalidation
- • STRO-004 efficacy is based on preliminary Phase 1 observations across multiple tumor types, including unconfirmed responses, and may not persist with additional follow-up or larger cohorts.
- • STRO-006 clinical entry, STRO-227 IND submission and the partnered Astellas program are execution-dependent and could be delayed.
- • STRO-004 evidence remains an early, heterogeneous Phase 1 dataset containing unconfirmed responses, while the maximum tolerated dose and go-forward dose were not yet established.
Catalyst clock
2026-09-30
STRO-006 clinical entry
Lead driver: Sentiment · See AI snapshot
Momentum
4
9% active weight
Current posture
7d trendFlat
Δ7d
-0.6
Δ21d
-6.1
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
100
62% active weight
Current posture
7d trendImproving
Δ7d
+22.6
Δ21d
+0.5
Why this grade
Composite grade A. Momentum 4.2 / Value 41.2 / Sentiment 100.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-12. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$17.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$369.43M
Beta
1.55
Shares Out
16.58M
P/E (TTM) · Derived
-1.0
P/S (TTM)
0.88
P/FCF (TTM) · Derived
-1.69
Rev YoY
-84.6%
EPS YoY
+71.0%
Gross Margin
+86.7%
Op Margin
-288.5%
Net Debt
$93.78M
Current Ratio
3.32
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data